Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e

Vaccine

Volumn 29, Issue 33, 2011, Pages 5481-5487

  Park, Ki Seok ^a   Seo, Yong Bok ^a   Lee, Ji Yeung ^b   Im, Se Jin ^a   Seo, Sang Hwan ^a   Song, Min Suk ^c   Choi, Young Ki ^c   Sung, Young Chul ^a,b  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b POSTECH Biotech Center   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

Author keywords

Cross protection; DNA; Electroporation; Fusion; HA; Influenza; M2e; Vaccine

Indexed keywords

DNA VACCINE; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX 2 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; AVIAN INFLUENZA VIRUS; CD8+ T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VIRUS A H5N2; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; DISEASE MODELS, ANIMAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA VACCINES; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; RODENT DISEASES; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

EID: 79960369896     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.062     Document Type: Article

References (33)

1. Hay A.J., Gregory V., Douglas A.R., Lin Y.P. The evolution of human influenza viruses. Philos Trans Roy Soc Lond B: Biol Sci 2001, 356(December (1416)):1861-1870.
2. WHO. WHO Global Influenza Surveillance Network. Available from: http://www.who.int/csr/disease/influenza/surveillance/en/index.html.
3. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995, 1(June (6)):583-587.
4. McMichael A.J., Gotch F., Cullen P., Askonas B., Webster R.G. The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 1981, 43(February (2)):276-284.
5. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986, 67(April (Pt 4)):719-726.
6. Jiang Y., Yu K., Zhang H., Zhang P., Li C., Tian G., et al. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antivir Res 2007, 75(September (3)):234-241.
7. Chen M.W., Cheng T.J., Huang Y., Jan J.T., Ma S.H., Yu A.L., et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 2008, 105(September (36)):13538-13543.
8. Ha S.J., Jeon B.Y., Youn J.I., Kim S.C., Cho S.N., Sung Y.C. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther 2005, 12(April (7)):634-638.
9. Kodihalli S., Kobasa D.L., Webster R.G. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000, 18(May (23)):2592-2599.
10. Xie H., Liu T., Chen H., Huang X., Ye Z. Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid. Vaccine 2007, 25(November (44)):7649-7655.
11. Ilyinskii P.O., Gabai V.L., Sunyaev S.R., Thoidis G., Shneider A.M. Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity. Cell Cycle 2007, 6(August (16)):2043-2047.
12. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A "universal" human influenza A vaccine. Virus Res 2004, 103(July (1-2)):173-176.
13. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(August (23-24)):2993-3003.
14. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(October (10)):1157-1163.
15. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(April (4)):499-508.
16. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F., Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172(May (9)):5598-5605.
17. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7(February (2)):171-177.
18. Seo S.H., Jin H.T., Park S.H., Youn J.I., Sung Y.C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009, 27(September (42)):5906-5912.
19. Park K.S., Lee J., Ahn S.S., Byun Y.H., Seong B.L., Baek Y.H., et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395(December (2)):182-189.
20. Seo S.H., Kim K.S., Park S.H., Shu Y.S., Kim S.J., Jenu S.S., et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gen Ther 2011, 18(May (5)):488-495.
21. Lee J.H., Pascua P.N., Song M.S., Baek Y.H., Kim C.J., Choi H.W., et al. Isolation and genetic characterization of H5N2 influenza viruses from pigs in Korea. J Virol 2009, 83(May (9)):4205-4215.
22. Nayak B., Kumar S., DiNapoli J.M., Paldurai A., Perez D.R., Collins P.L., et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 2010, 84(March (5)):2408-2420.
23. Larke N., Im E.J., Wagner R., Williamson C., Williamson A.L., McMichael A.J., et al. Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol 2007, 37(February (2)):566-577.
24. Sedegah M., Charoenvit Y., Minh L., Belmonte M., Majam V.F., Abot S., et al. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 2004, 11(March (5)):448-456.
25. Choi S.Y., Suh Y.S., Cho J.H., Jin H.T., Chang J., Sung Y.C. Enhancement of DNA vaccine-induced immune responses by influenza virus NP gene. Immune Network 2009, 9(October (5)):169-178.
26. Fomsgaard A., Nielsen H.V., Bryder K., Nielsen C., Machuca R., Bruun L., et al. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen. Scand J Immunol 1998, 47(April (4)):289-295.
27. Boon A.C., de Mutsert G., van Baarle D., Smith D.J., Lapedes A.S., Fouchier R.A., et al. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 2004, 172(February (4)):2453-2460.
28. Takamura S., Matsuo K., Takebe Y., Yasutomi Y. Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol 2005, 175(August (4)):2541-2547.
29. Park S.H., Chang J., Yang S.H., Kim H.J., Kwak H.H., Kim B.M., et al. Enhancement of antigen-specific antibody and CD8+ T cell responses by codelivery of IL-12-encapsulated microspheres in protein and peptide vaccination. Immune Network 2007, 7(December (04)):186-196.
30. Eliasson D.G., El Bakkouri K., Schon K., Ramne A., Festjens E., Lowenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26(February (9)):1243-1252.
31. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(February (4)):1959-1964.
32. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367(February (9509)):475-481.
33. Yewdell J.W., Bennink J.R., Smith G.L., Moss B., Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985, 82(March (6)):1785-1789.